SCHEMBL20135698

SCHEMBL20135698

Cc1cccc2nc(C3CCN(C(=O)c4ccc([C@@]5(C(C)C)NC(=O)NC5=O)cc4)CC3)oc12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.45
THRB P10828 1/20 0.45
HTR2B P41595 1/20 0.44
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 2/20 0.42
USP2 O75604 1/20 0.41
MGLL Q99685 2/20 0.37
UBE2M P61081 1/20 0.37
DCUN1D1 Q96GG9 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135699 1.00 LMNA (0.45) LMNATHRBHTR2BMAPTALDH1A1
SCHEMBL20135254 0.88 LMNA (0.46) LMNATHRBHTR2BMAPTALDH1A1
SCHEMBL20135250 0.88 LMNA (0.46) LMNATHRBHTR2BMAPTALDH1A1
SCHEMBL20135454 0.87 LMNA (0.62) LMNATHRBHTR2BMAPTALDH1A1
SCHEMBL20135457 0.87 LMNA (0.62) LMNATHRBHTR2BMAPTALDH1A1
SCHEMBL20135177 0.85 LMNA (0.42) LMNATHRBHTR2BMAPTALDH1A1
SCHEMBL20135178 0.85 LMNA (0.42) LMNATHRBHTR2BMAPTALDH1A1
SCHEMBL20135105 0.84 LMNA (0.47) LMNATHRBHTR2BMAPTALDH1A1
SCHEMBL20135107 0.84 LMNA (0.47) LMNATHRBHTR2BMAPTALDH1A1
SCHEMBL20134856 0.83 LMNA (0.43) LMNATHRBHTR2BMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 LMNA 4264/4885THRB 4280/4885HTR2B 2669/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 LMNA 4113/4885THRB 4174/4885HTR2B 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.